Immunomodulatory action of dietary fish oil and targeted deletion of intestinal epithelial cell PPAR δ in inflammation-induced colon carcinogenesis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 1, 2012, Pages

  Monk, Jennifer M ^a   Kim, Wooki ^a   Callaway, Evelyn ^a   Turk, Harmony F ^a   Foreman, Jennifer E ^b   Peters, Jeffrey M ^b   He, Weimin ^c   Weeks, Brad ^d   Alaniz, Robert C ^c   McMurray, David N ^a,c   Chapkin, Robert S ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Chronic inflammation; Malignant transformation; Peroxisome proliferator activated receptor ; T cell

Indexed keywords

AZOXYMETHANE; CD44V ANTIGEN; CYTOKINE; DEXTRAN SULFATE; FISH OIL; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CARCINOGENESIS; CONTROLLED STUDY; ENTERITIS; FEMALE; GENE DELETION; GENE EXPRESSION; IMMUNOMODULATION; INTESTINE EPITHELIUM CELL; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; T LYMPHOCYTE ACTIVATION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD11A; ANTIGENS, CD44; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CHRONIC DISEASE; COLITIS; COLONIC NEOPLASMS; CYTOKINES; DIETARY FATS, UNSATURATED; FEMALE; FISH OILS; GENE DELETION; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; PPAR DELTA; SPLEEN; STAT3 TRANSCRIPTION FACTOR;

EID: 83755207011     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00315.2011     Document Type: Article

References (104)

1. Abraham C, Griffith J, Miller J. The dependence for leukocyte function- associated antigen-1/ICAM-1 interactions in T cell activation cannot be overcome by expression of high density TCR ligand. J Immunol 162: 4399-4405, 1999.
2. Akiyama TE, Meinke PT, Berger JP. PPAR ligands: potential therapies for metabolic syndrome. Curr Diab Rep 5: 45-52, 2005.
3. Baaten BJ, Li CR, Deiro MF, Lin MM, Linton PJ, Bradley LM. CD44 regulates survival and memory development in Th1 cells. Immunity 32: 104-115, 2010.
4. Bachmann MF, McKall-Faienza K, Schmits R, Bouchard D, Beach J, Speiser DE, Mak TW, Ohashi PS. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7: 549-557, 1997.
5. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM. Effects of peroxisome proliferator-activated receptor-δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99: 303-308, 2002.
6. Bassaganya-Riera J, Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 25: 454-465, 2006.
7. Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F. Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr 71: 339S-342S, 2000.
8. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334: 1557-1560, 1996.
9. Bingaman AW, Patke DS, Mane VR, Ahmadzadeh M, Ndejembi M, Bartlett ST, Farber DL. Novel phenotypes and migratory properties distinguish memory CD4 T cell subsets in lymphoid and lung tissue. Eur J Immunol 35: 3173-3186, 2005.
10. Bland PW, Warren LG. Antigen presentation by epithelial cells of the rat small intestine. I. Kinetics, antigen specificity and blocking by anti-Ia antisera. Immunology 58: 1-7, 1986.
11. Buning J, Schmitz M, Repenning B, Ludwig D, Schmidt MA, Strobel S, Zimmer KP. Interferon-γ mediates antigen trafficking to MHC class II-positive late endosomes of enterocytes. Eur J Immunol 35: 831-842, 2005.
12. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM. The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell Signal 18: 9-20, 2006.
13. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83: 1505S-1519S, 2006.
14. Chang WC, Chapkin RS, Lupton JR. Predictive value of proliferation, differentiation and apoptosis as intermediate markers for colon tumorigenesis. Carcinogenesis 18: 721-730, 1997.
15. Chapkin RS, Davidson LA, Ly L, Weeks BR, Lupton JR, McMurray DN. Immunomodulatory effects of (n-3) fatty acids: putative link to inflammation and colon cancer. J Nutr 137: 200S-204S, 2007.
16. Chapkin RS, McMurray DN, Lupton JR. Colon cancer, fatty acids and anti-inflammatory compounds. Curr Opin Gastroenterol 23: 48-54, 2007.
17. Dahan S, Roth-Walter F, Arnaboldi P, Agarwal S, Mayer L. Epithelia: lymphocyte interactions in the gut. Immunol Rev 215: 243-253, 2007.
18. Davidson LA, Lupton JR, Jiang YH, Chapkin RS. Carcinogen and dietary lipid regulate ras expression and localization in rat colon without affecting farnesylation kinetics. Carcinogenesis 20: 785-791, 1999.
19. Davidson LA, Nguyen DV, Hokanson RM, Callaway ES, Isett RB, Turner ND, Dougherty ER, Wang N, Lupton JR, Carroll RJ, Chapkin RS. Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Res 64: 6797-6804, 2004.
20. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2: 748-759, 2002.
21. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 183: 1119-1130, 1996.
22. Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, Takahashi H, Sun HW, Kanno Y, Powrie F, O'Shea JJ. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32: 605-615, 2010.
23. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 16: 201-223, 1998.
24. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 30: 80-89, 2010.
25. el Marjou F, Janssen KP, Chang BH, Li M, Hindie V, Chan L, Louvard D, Chambon P, Metzger D, Robine S. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39: 186-193, 2004.
26. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132: 2359-2370, 2007.
27. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142: 4195-4202, 2001.
28. Fan YY, Ly LH, Barhoumi R, McMurray DN, Chapkin RS. Dietary docosahexaenoic acid suppresses T cell protein kinase C-θ lipid raft recruitment and IL-2 production. J Immunol 173: 6151-6160, 2004.
29. Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS. Chemopreventive n-3 fatty acids activate RXRα in colonocytes. Carcinogenesis 24: 1541-1548, 2003.
30. Fitzgerald KA, O'Neill LA. Characterization of CD44 induction by IL-1: a critical role for Egr-1. J Immunol 162: 4920-4927, 1999.
31. Foger N, Marhaba R, Zoller M. Involvement of CD44 in cytoskeleton rearrangement and raft reorganization in T cells. J Cell Sci 114: 1169-1178, 2001.
32. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferatoractivated receptors-α and -δ. Proc Natl Acad Sci USA 94: 4312-4317, 1997.
33. Gill N, Wlodarska M, Finlay BB. The future of mucosal immunology: studying an integrated system-wide organ. Nat Immunol 11: 558-560, 2010.
34. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM. Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem Biophys Res Commun 371: 456-461, 2008.
35. Giurisato E, McIntosh DP, Tassi M, Gamberucci A, Benedetti A. T cell receptor can be recruited to a subset of plasma membrane rafts, independently of cell signaling and attendantly to raft clustering. J Biol Chem 278: 6771-6778, 2003.
36. Grimaldi PA. Regulatory role of peroxisome proliferator-activated receptor- δ (PPAR-δ) in muscle metabolism. A new target for metabolic syndrome treatment? Biochimie 87: 5-8, 2005.
37. Harder T, Engelhardt KR. Membrane domains in lymphocytes-from lipid rafts to protein scaffolds. Traffic 5: 265-275, 2004.
38. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat Med 10: 481-483, 2004.
39. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum 34: 1434-1443, 1991.
40. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, Xu H. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 184: 2281-2288, 2010.
41. Hershberg RM, Cho DH, Youakim A, Bradley MB, Lee JS, Framson PE, Nepom GT. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells. J Clin Invest 102: 792-803, 1998.
42. Hershberg RM, Framson PE, Cho DH, Lee LY, Kovats S, Beitz J, Blum JS, Nepom GT. Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing. J Clin Invest 100: 204-215, 1997.
43. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512, 2005.
44. Hollingshead HE, Morimura K, Adachi M, Kennett MJ, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPAR β/δ protects against experimental colitis through a ligand-independent mechanism. Dig Dis Sci 52: 2912-2919, 2007.
45. Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, Rasanen L, Kolho KL, Farkkila M, Savilahti E, Vaarala O. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis 14: 1175-1184, 2008.
46. Hong MY, Chapkin RS, Morris JS, Wang N, Carroll RJ, Turner ND, Chang WC, Davidson LA, Lupton JR. Anatomical site-specific re- sponse to DNA damage is related to later tumor development in the rat azoxymethane colon carcinogenesis model. Carcinogenesis 22: 1831-1835, 2001.
47. Hruz P, Dann SM, Eckmann L. STAT3 and its activators in intestinal defense and mucosal homeostasis. Curr Opin Gastroenterol 26: 109-115, 2010.
48. Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, Kang JX. Transgenic mice rich in endogenous w-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 103: 11276-11281, 2006.
49. Irons R, Fritsche KL. n-3 PUFA fail to affect in vivo, antigen-driven CD8+ T-cell proliferation in the spleen of naive mice. Br J Nutr 95: 838-844, 2006.
50. Itzkowitz SH, Yio X. Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287: G7-G17, 2004.
51. Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer-more than a "gut" feeling? Cell Div 5: 14, 2010.
52. Jia Q, Ivanov I, Zlatev Z, Alaniz RC, Weeks BR, Callaway E, Goldsby JS, Davidson LA, Fan YY, Zhou L, Lupton JR, McMurray DN, Chapkin RS. Dietary fish oil and cucumin combine to modulate colonic cytokinetics and gene expression in dextran sodium sulphatetreated mice. Br J Nutr 106: 519-529, 2011.
53. Jia Q, Lupton JR, Smith R, Weeks BR, Callaway E, Davidson LA, Kim W, Fan YY, Yang P, Newman RA, Kang JX, McMurray DN, Chapkin RS. Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice. Cancer Res 68: 3985-3991, 2008.
54. Kilgore KS, Billin AN. PPAR β/δ ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 9: 463-469, 2008.
55. Kim W, Fan YY, Barhoumi R, Smith R, McMurray DN, Chapkin RS. n-3 polyunsaturated fatty acids suppress the localization and activation of signaling proteins at the immunological synapse in murine CD4+ T cells by affecting lipid raft formation. J Immunol 181: 6236-6243, 2008.
56. Kim W, Khan NA, McMurray DN, Prior IA, Wang N, Chapkin RS. Regulatory activity of polyunsaturated fatty acids in T-cell signaling. Prog Lipid Res 49: 250-261, 2010.
57. Kim W, McMurray DN, Chapkin RS. n-3 polyunsaturated fatty acids- physiological relevance of dose. Prostaglandins Leukot Essent Fatty Acids 82: 155-158, 2010.
58. Kong SC, Hurlstone DP, Pocock CY, Walkington LA, Farquharson NR, Bramble MG, McAlindon ME, Sanders DS. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 39: 138-141, 2005.
59. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15: 114-123, 2009.
60. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M. IL-23 promotes tumour incidence and growth. Nature 442: 461-465, 2006.
61. Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol 4: 325-335, 2004.
62. Madden J, Shearman CP, Dunn RL, Dastur ND, Tan RM, Nash GB, Rainger GE, Brunner A, Calder PC, Grimble RF. Altered monocyte CD44 expression in peripheral arterial disease is corrected by fish oil supplementation. Nutr Metab Cardiovasc Dis 19: 247-252, 2009.
63. Maloy KJ, Kullberg MC. IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunol 1: 339-349, 2008.
64. Maniati E, Soper R, Hagemann T. Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29: 5653-5662, 2010.
65. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator- activated receptor-β inhibits colon carcinogenesis. Cancer Res 66: 4394-4401, 2006.
66. Mayer L, Eisenhardt D, Salomon P, Bauer W, Plous R, Piccinini L. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease. Gastroenterology 100: 3-12, 1991.
67. Mayer L, Shlien R. Evidence for function of Ia molecules on gut epithelial cells in man. J Exp Med 166: 1471-1483, 1987.
68. Munkholm P. The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18 Suppl 2: 1-5, 2003.
69. Nakazawa A, Watanabe M, Kanai T, Yajima T, Yamazaki M, Ogata H, Ishii H, Azuma M, Hibi T. Functional expression of costimulatory molecule CD86 on epithelial cells in the inflamed colonic mucosa. Gastroenterology 117: 536-545, 1999.
70. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627, 2003.
71. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 98: 2598-2603, 2001.
72. Pavlick KP, Ostanin DV, Furr KL, Laroux FS, Brown CM, Gray L, Kevil CG, Grisham MB. Role of T-cell-associated lymphocyte function- associated antigen-1 in the pathogenesis of experimental colitis. Int Immunol 18: 389-398, 2006.
73. Peters JM, Hollingshead HE, Gonzalez FJ. Role of peroxisomeproliferator- activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin Sci (Lond) 115: 107-127, 2008.
74. Podolsky DK. Inflammatory bowel disease. N Engl J Med 347: 417-429, 2002.
75. Prescott SM, Stenson WF. Fish oil fix. Nat Med 11: 596-598, 2005.
76. Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, Peters JM, Clarke AR. PPARδ status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23: 8992-8996, 2004.
77. Rubin DT, Kavitt RT. Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am 35: 581-604, 2006.
78. Sanderson P, Calder PC. Dietary fish oil diminishes lymphocyte adhesion to macrophage and endothelial cell monolayers. Immunology 94: 79-87, 1998.
79. Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 16: 1808-1813, 2010.
80. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407, 2006.
81. Schulz TJ, Glaubitz M, Kuhlow D, Thierbach R, Birringer M, Steinberg P, Pfeiffer AF, Ristow M. Variable expression of Cre recombinase transgenes precludes reliable prediction of tissue-specific gene disruption by tail-biopsy genotyping. PLos One 2: e1013, 2007.
82. Schwerbrock NM, Karlsson EA, Shi Q, Sheridan PA, Beck MA. Fish oil-fed mice have impaired resistance to influenza infection. J Nutr 139: 1588-1594, 2009.
83. Selby WS, Janossy G, Mason DY, Jewell DP. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol 53: 614-618, 1983.
84. Springer TA. Adhesion receptors of the immune system. Nature 346: 425-434, 1990.
85. Stenson WF, Cort D, Rodgers J, Burakoff R, DeSchryver-Kecskemeti K, Gramlich TL, Beeken W. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 116: 609-614, 1992.
86. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 20: 495-549, 2002.
87. Swamy M, Jamora C, Havran W, Hayday A. Epithelial decision makers: in search of the "epimmunome." Nat Immunol 11: 656-665, 2010.
88. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, Hosokawa M. Ligands for peroxisome proliferator-activated receptors-α and -γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 61: 2424-2428, 2001.
89. Turk HF, Kolar SS, Fan YY, Cozby CA, Lupton JR, Chapkin RS. Linoleic acid and butyrate synergize to increase Bcl-2 levels in colonocytes. Int J Cancer 128: 63-71, 2011.
90. Vainer B, Horn T, Nielsen OH. Colonic epithelial cell expression of ICAM-1 relates to loss of surface continuity: a comparative study of inflammatory bowel disease and colonic neoplasms. Scand J Gastroenterol 41: 318-325, 2006.
91. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206: 1457-1464, 2009.
92. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARδ and PPARγ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc Natl Acad Sci USA 100: 6712-6717, 2003.
93. Wirth TC, Badovinac VP, Zhao L, Dailey MO, Harty JT. Differentiation of central memory CD8 T cells is independent of CD62Lmediated trafficking to lymph nodes. J Immunol 182: 6195-6206, 2009.
94. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15: 1016-1022, 2009.
95. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3: 397-403, 1999.
96. Yang L, Zhang H, Zhou ZG, Yan H, Adell G, Sun XF. Biological function and prognostic significance of peroxisome proliferator-activated receptor-δ in rectal cancer. Clin Cancer Res 17: 3760-3770, 2011.
97. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316, 2006.
98. Yog R, Barhoumi R, McMurray DN, Chapkin RS. n-3 polyunsaturated fatty acids suppress mitochondrial translocation to the immunologic synapse and modulate calcium signaling in T cells. J Immunol 184: 5865-5873, 2010.
99. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004.
100. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809, 2009.
101. Yu QT, Saruta M, Avanesyan A, Fleshner PR, Banham AH, Papadakis KA. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 13: 191-199, 2007.
102. Zhang P, Kim W, Zhou L, Wang N, Ly LH, McMurray DN, Chapkin RS. Dietary fish oil inhibits antigen-specific murine Th1 cell development by suppression of clonal expansion. J Nutr 136: 2391-2398, 2006.
103. Zhang X, Young HA. PPAR and immune system-what do we know? Int Immunopharmacol 2: 1029-1044, 2002.
104. Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM, Shureiqi I. Targeted genetic disruption of peroxisome proliferatoractivated receptor-δ and colonic tumorigenesis. J Natl Cancer Inst 101: 762-767, 2009.